vimarsana.com

Hepcidin Mimetic Peptide News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Takeda and Protagonist ink global license and development deal worth $1 7B for hematology asset rusfertide

Takeda Pharmaceutical Co. Ltd. and Protagonist Therapeutics Inc. have inked a global development and commercialization deal worth up to $1.7 billion for Protagonist’s rusfertide for treatment of polycythemia vera (PV), a rare and chronic blood disorder affecting bone marrow.

Takeda and Protagonist ink global license and development deal worth $1 7B for hematology asset rusfertide

Takeda Pharmaceutical Co. Ltd. and Protagonist Therapeutics Inc. have inked a global development and commercialization deal worth up to $1.7 billion for Protagonist’s rusfertide for treatment of polycythemia vera (PV), a rare and chronic blood disorder affecting bone marrow.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.